nVerses Capital’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
BBA
KCM
nVerses Capital's SMMT Position: Q3 2026 in Review
nVerses Capital sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 17,749 shares — an estimated $259K sold.
nVerses Capital first reported a position in SMMT in Q2 2026 and held it in 1 quarter. The position peaked at $259K in Q2 2026. 295 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- nVerses Capital reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
- nVerses Capital sold 17,749 Summit Therapeutics shares in Q3 2026, an estimated $259K.
- nVerses Capital first reported a position in Summit Therapeutics in Q2 2026 and held it in 1 quarter.
- nVerses Capital's Summit Therapeutics position peaked at $259K in Q2 2026.
- 295 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on nVerses Capital's 13F filing for Q3 2026.